ACCRUFeR Pediatric PK Results to be Presented

AI SummaryClose X

Shield Therapeutics plc announced that pharmacokinetic results from a Phase 3 pediatric trial of ACCRUFeR® (ferric maltol) will be presented at the American Society of Hematology Conference, confirming its suitability for iron replacement in children as young as one month. The study demonstrated that iron was well-absorbed at age-appropriate doses, and maltol was rapidly metabolized and excreted without accumulation across all age groups, including infants. These findings are crucial for supporting the US FDA's Priority Review to extend ACCRUFeR®'s indication to adolescents aged 10 and above, and potentially to an infant population with an unmet need for safe and effective oral iron treatment.

Disclaimer*

UK 100

Latest directors dealings